UBS Increases Stake in Verve Therapeutics by 623.3%: A Bold Move Escalating the Biopharmaceutical Company’s Worth
As of the latest filing with the Securities & Exchange Commission, UBS Group AG has increased its position in Verve ...
Tag: VERV
TD Asset Management Increases Stake in Verve Therapeutics Amid Growing Confidence in Biotech Company
TD Asset Management Inc. has recently upped its stake in Verve Therapeutics, Inc. by 83.6%, acquiring an additional 11,320 shares ...
Institutional Investor SG Americas Securities LLC Increases Position in Verve Therapeutics by 96.2%: A Bullish Outlook on the Future of Cardiovascular Biotech
In a recent report, it has been found that one of the institutional investors, SG Americas Securities LLC, has recently ...
Sumitomo Mitsui Trust Holdings Inc. Increases Stake in Verve Therapeutics by 58.4%: A Major Sign of Investment Appetite for Innovative Biotech Companies
In a move that has raised eyebrows throughout the financial community, Sumitomo Mitsui Trust Holdings Inc. recently announced that it ...
Verve Therapeutics Leads the Way in Cardiovascular Disease Treatment with Groundbreaking Gene Editing Therapy.
Verve Therapeutics, an innovative genetic medicines company, has recently released its quarterly earnings data. Boasting a beat in analysts' consensus ...